Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Canaccord Genuity has raised its price target on LSI Industries to $27, reflecting confidence in the company’s sustained revenue growth and prudent capital management. Despite a slight earnings per share miss in its recent quarterly report, LSI’s top-line results exceeded expectations, signaling positive momentum in its operational execution. The s…
Jefferies has updated its perspective on German automotive suppliers, highlighting a challenging environment in 2026 marked by subdued production, heightened competition, and constrained prospects for sales and margin improvements. Despite the overall difficult market forecast, Schaeffler emerges as Jefferies’ preferred investment due to its strate…
Canaccord Genuity increased its price target for Corcept Therapeutics to $100 from $99, maintaining a Buy rating based on encouraging clinical results for relacorilant in treating platinum-resistant ovarian cancer (PROC). Despite regulatory challenges in other indications, the company remains financially robust with expectations for substantial rev…
KeyBanc Capital Markets has reaffirmed its Overweight rating on Salesforce.com with a price target of $400, pointing to the company's expanding opportunities in the Life Sciences Cloud market. Despite trading near its yearly lows, Salesforce's prospects remain promising as it intensifies its competition with Veeva and progressively incorporates AI-…
Bernstein SocGen Group has trimmed its price target for McCormick shares to $85 from $87 in response to the company's subdued fiscal 2026 guidance. The research firm kept its Outperform rating but highlighted several headwinds affecting growth projections, including weaker-than-expected organic sales, earnings per share shortfall, elevated tax rate…
Goldman Sachs maintains a Neutral rating and a $26 price target on Pfizer stock as the firm faces a patent cliff that pressures revenue growth. Despite trading near its 52-week high and below peer valuation multiples, Pfizer's share price has been range-bound. Key upcoming clinical data in 2026—including trials in obesity and lung cancer—are antici…
Canaccord Genuity has adjusted its price target for Mobileye N.V to $24 from $30 due to a conservative assessment of Volkswagen’s production ramp, while keeping a Buy rating on the stock. Despite recent quarterly earnings below expectations and a significant stock price decline, analysts see upside potential as the company aims for profitability by…
Guggenheim has reaffirmed its Buy rating on Reddit (NYSE:RDDT), maintaining a $245 price target based on the platform's advancements in user engagement and promising revenue growth forecasts. Despite current market value suggesting some overvaluation, analysts anticipate significant upside driven by product enhancements and expanded advertising ado…
KeyBanc has increased its price target for Worthington Steel Inc to $47 from $41, maintaining an Overweight rating amid the company's plan to acquire Klöckner & Co. The deal, expected to close in the latter half of 2026, positions Worthington Steel as the second largest steel service center in North America, boosting its long-term earnings prospect…
Wolfe Research has adjusted its price target on Capital One Financial downward from $294 to $280 while maintaining an Outperform rating. The revision is primarily motivated by higher anticipated marketing and operating expenses. Although earnings per share estimates have been trimmed for 2026 and 2027, the stock is still expected to deliver signifi…
KeyBanc has confirmed its Sector Weight rating on Apple shares, highlighting a balanced near-term risk and reward outlook. KeyBanc upgraded its fiscal first-quarter outlook driven by anticipated gains in iPhone average selling prices and stronger Mac sales, while noting potential challenges for the second half of the fiscal year. Market analysts ma…
At the World Economic Forum in Davos, leading finance officials converged to debate the evolution of the global order. While some voices warned of a breach in international cooperation marked by power struggles, key figures, including the European Central Bank President and the International Monetary Fund chief, advocated viewing the developments a…
Morgan Stanley analysts foresee a notable 20% increase in U.S. individual tax refunds in the first quarter of 2026, driven by comprehensive budget legislation. These elevated refunds, amounting to approximately $350 billion by May’s end, are projected to propel personal incomes and bolster consumer expenditure, an essential component of the economy…
Needham has upheld its Hold rating on Intel following a fourth-quarter financial performance that surpassed earnings expectations but was tempered by below-par revenue guidance and persistent supply constraints. Intel's stock has shown remarkable gains over the past year, yet concerns linger over its forward outlook and production bottlenecks impac…
Leerink Partners has upgraded Relmada Therapeutics Inc from Market Perform to Outperform, assigning a price target significantly higher than the current stock price, based on the potential of Relmada's bladder cancer drug NDV-01. After discontinuing its previous depression therapy REL-1017, Relmada is focusing on oncology with NDV-01, a sustained-r…
European Union leaders are galvanizing efforts to confront what they view as the escalating assertiveness of the United States under President Donald Trump, following a diplomatic standoff over Greenland. The incident has underscored the urgency of stabilizing the transatlantic partnership and reducing Europe’s economic and security vulnerabilities…
UBS is preparing to introduce cryptocurrency trading capabilities to a select group of private banking clients in Switzerland, with plans for potential expansion into other global markets such as Asia-Pacific and the United States. This initiative reflects growing client interest in digital assets and positions UBS alongside other major financial i…
JPMorgan has lifted its price target for Intel Corporation to $35 from $30, citing robust demand for server CPUs as a key driver, despite guidance that fell short of analyst expectations. Intel’s stock currently trades significantly above JPMorgan’s revised target, reflecting strong market gains. While supply challenges are anticipated to ease, con…
Keefe, Bruyette & Woods (KBW) has increased the price target for Equity Bancshares (NYSE: EQBK) from $47.00 to $49.00 while keeping its Market Perform rating. This decision follows Equity Bancshares' notable earnings performance with EPS surpassing projections despite marginally lower pre-provision net revenue. The institution demonstrated robust r…
Keefe, Bruyette & Woods (KBW) has raised its price target for Great Southern Bancorp (NASDAQ: GSBC) to $63 from $61, following the company’s robust fourth-quarter 2025 earnings report. The bank’s earnings per share and revenue exceeded expectations, supported by stable net interest margins, increased fee income, and controlled expenses. Despite som…
Keefe, Bruyette & Woods raised its price target on Horizon Bancorp to $21 from $19, endorsing an Outperform rating after the bank reported better-than-expected earnings. The bank’s higher pre-provision net revenue and net interest margin contributed to stronger top-line performance. Updated guidance and optimistic margin outlook prompted increased …
Keefe, Bruyette & Woods has increased its price objective for Banc of California to $23, citing robust growth metrics and return improvements that support the stock's valuation. The bank's latest earnings surpassed expectations, reinforcing confidence among analysts and prompting revisions to future earnings projections.
RBC Capital has increased the price target for Definium Therapeutics Inc to $36 from $20 and reaffirmed an Outperform rating. This adjustment is based on heightened expectations for the commercial success of Definium’s lead candidate, DT120, currently in late-stage trials for generalized anxiety disorder. The company’s market value stands near $1.6…
Keefe, Bruyette & Woods has increased its price target for Live Oak Bancshares to $146 from $132 and maintained an Outperform rating after the bank's fourth-quarter results exceeded analyst estimates. The bank showcased stronger-than-expected earnings and revenue growth while maintaining stable credit performance. However, KBW anticipates a reversa…
RBC Capital has increased its price target for Compass Pathways to $21, maintaining an Outperform rating amid advancing clinical developments and promising market insights from recent psychedelics symposiums. The company’s shares have shown notable gains over the past year, with excitement building ahead of upcoming trial data.
